http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant
-
Curiosity Cube 2025: MilliporeSigma’s Mobile Science Labs Tour Globally to Bring STEM Education to Students
-
MilliporeSigma Partners with Opentrons Labworks, Inc., Supporting Lab of the Future
-
MilliporeSigma Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio
-
MilliporeSigma to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio
-
MilliporeSigma Invests $76 Million to Expand ADC Manufacturing for Novel Cancer Therapies
-
MilliporeSigma Opens New €290 Million Biosafety Testing Facility in Rockville, Maryland, USA
-
MilliporeSigma Launches Single-Use Reactor Designed to Accelerate Antibody Drug Conjugate Manufacturing
-
MilliporeSigma Receives Industry First EXCiPACT Certification for Cell Culture Media Manufacturing
-
MilliporeSigma Announces Closing of Mirus Bio Acquisition, Bolstering Viral Vector Bioprocessing Offering
-
MilliporeSigma and The Michael J. Fox Foundation Offer Service to Advance Parkinson’s Research
-
MilliporeSigma Announces Siren Biotechnology as Winner of its North American Advance Biotech Grant
-
MilliporeSigma Launches First Software for Complete Data Traceability in Microbial Quality Control
-
MilliporeSigma Signs Definitive Agreement to Acquire Mirus Bio, Furthering Ambition to Be a Leading Supplier for Viral Vector Manufacturing
-
MilliporeSigma Inspires Students to Explore STEM Careers with 2024 Curiosity Cube Tour
-
MilliporeSigma Launches First All-in-One Genetic Stability Assay to Accelerate Biosafety Testing
-
MilliporeSigma Invests More than € 300 Million in New Life Science Production Site in Korea
-
MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA Services
-
MilliporeSigma Invests $25 Million to Expand Cell Culture Media Production in Kansas
-
Athinia™ expands partnerships to include Tokyo Electron for real-time collaborative analytics of semiconductor fab equipment performance
-
MilliporeSigma Announces Proteologix as Winner of its North American Advance Biotech Grant
-
Merck KGaA, Darmstadt, Germany Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab)
-
MilliporeSigma Gains Leading Perfusion Micro-Bioreactor with Erbi Biosystems Acquisition
-
MilliporeSigma Invests $ 286 Million in U.S. Drug Safety Testing Capacity
-
MilliporeSigma Announces a Boost in Commercial Capacity in France as Part of New Millipore® CTDMO Services
-
MilliporeSigma Announces Investment of More Than € 130 Million to Strengthen Manufacturing Capabilities in Molsheim, France
-
MilliporeSigma Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production Platform
-
MilliporeSigma Breaks Ground on Company's First Lateral Flow Membrane Production Facility in the United States
-
Micron to Select Athinia™ for Pioneering Data Collaboration
-
MilliporeSigma Opens US$ 65 Million CDMO Facility to Address Demand for Critical Cancer Therapies
-
MilliporeSigma Announces the Expansion of Hands-On Science Education Program with Kick-off of Global Curiosity Cube® Mobile Lab
-
MilliporeSigma Announces Acquisition of MAST® Platform from Lonza, a Leading Automated Bioreactor Sampling System to Advance BioProcessing Capabilities
-
EMD Serono Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022
-
MilliporeSigma Announces Closing of Exelead Acquisition and Plans to Invest More Than € 500 Million in Technology Scale-Up
-
European Commission Approves TEPMETKO® (tepotinib) for Patients with Advanced NSCLC with METex14 Skipping Alterations
-
MilliporeSigma Announces Organizational Transformation to Strengthen CDMO Offering and Accelerate Future Growth
-
MilliporeSigma Announces $136.7 Million U.S. Government Contract Award for New Lateral Flow Membrane Production Facility in Sheboygan, Wisconsin
-
TEPMETKO® (tepotinib) Receives Positive CHMP Opinion for Patients with Advanced NSCLC with METex14 Skipping Alterations
-
New Data Show Dramatic Emotional Toll of Pandemic on Unpaid Caregivers of People Living With Cancer, Affecting Mental Health and Relationships
-
MilliporeSigma Announces New Innovation & Capacity to Advance Next Generation Antibody-drug Conjugate (ADC) Therapies
-
MilliporeSigma Announces Completion of New Viral Vector Contract Development Manufacturing Facility for Gene Therapy
-
EMD Serono Completes Enrollment of Evobrutinib Phase III Clinical Trials Ahead of ECTRIMS 2021
-
MilliporeSigma Accelerates Scale Up of Lipids to Meet Covid-19 Demand
-
MilliporeSigma Accelerates European Expansion Plans for Single-use Products Critical to Manufacturing Vaccines and Lifesaving Therapies
-
European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
-
MilliporeSigma Acquires AmpTec to Expand mRNA Capabilities for Vaccines, Treatments and Diagnostics
-
BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
-
MilliporeSigma Expands Production Capacities
-
MilliporeSigma Celebrates Topping-Out Ceremony for New Membrane Production Plant
-
MilliporeSigma Inaugurates New, Upgraded Onsite Industrial Water Treatment Plant
